ASCO Supports Expanded Adjuvant Therapy for Early Breast Cancer

October 1, 2018 – Patients with early-stage breast cancer facing a high risk of recurrence would benefit from the expanded use of adjuvant therapy, according to updated guidelines from the American Society of Clinical Oncoogy (ASCO). The recommendations cover clinical scenarios for patients with residual invasive HER2-negative disease after surgery and those with HER2-positive tumors who are candidates for additional targeted therapy. The ASCO guidelines are … (leggi tutto)